Cipla launches generic hepatitis C drug in India

By: | Published: December 21, 2015 4:39 PM

Cipla MD and Global Chief Executive Officer Subhanu Saxena said, "The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus."

Cipla stakeThe company’s product is a generic version of the S-based drug maker Gilead Sciences Inc’s Harvoni tablets. (Reuters photo)

Drug major Cipla has launched generic tablets used for treating of hepatitis C under the brand name ‘Hepcvir-L’ costing Rs 25,000 for a bottle of 28 tablets in India.

Cipla MD and Global Chief Executive Officer Subhanu Saxena said, “The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus.”

The company’s product is a generic version of the S-based drug maker Gilead Sciences Inc’s Harvoni tablets.

“Globally, the burden of Hepatitis C is around 185 million. About 12-18 million Indians are infected with this disease,” it added.

Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients, Cipla said.

The company’s current portfolio includes over 1,500 products across therapeutic categories.

Cipla was trading at Rs 646.15, up 0.62 per cent, on the BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition